Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50)

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vorapaxar (Primary)
  • Indications Cardiovascular disorders; Myocardial infarction; Peripheral arterial disorders; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms TRA-2P; TRA2degP-TIMI50; TRA2P-TIMI 50
  • Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough Research Institute

    • Most Recent Events

    • 28 Aug 2023 Results of pooled analysis (n=28892) from TRA2P-TIMI 50 and FOURIER assessing the association between Lp(a) and specific limb outcomes in patients with stable atherosclerotic vascular disease presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
    • 07 Nov 2022 Results assessing short- and long-term effects of vorapaxar (V) as compared to Placebo (PL) on the following biomarkers: Angiopoietin-2 (ANGPT2), Angiopoietin-like 4 (ANGPTL4), VEGF, ICAM-1, VCAM-1, E-Selectin (ESEL), von Willebrand Factor (VWF), Thrombomodulin (TM), PAI-1 and PAI-2 from TRA2P-TIMI 50 and TRACER presented at the American Heart Association Scientific Sessions 2022
    • 19 Jul 2022 Results published in the Clinical Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top